Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOGIAC
2024-511906-21-00Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in giant cell arteritis (GCA) comparing Tocilizumab + steroids with Placebo of tocilizumab + steroids (2 arms). Primary endpoint: Composite complete remission of giant cell arteritis with cerebrovascular involvement at 24 weeks. Started Nov 2024; status: completed.
02
Drugs
tocilizumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on 2024-511906-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511906-21-00.